GenOdyssee Has Received Notice of Allowance of European Patent Application
Covering Its Core Natural Evolution Technology Invented in 2002, and Received Broad Product Applications Protection Rights to All Cytokine
PARIS, October 24 /PRNewswire/ -- GenOdyssee (GO), a biotechnology company dedicated to the discovery and development of improved 'next generation' human protein therapeutics, announced today that it has received notice of allowance from the European Patent Office of its Patent Application no.3 785 733.1 (PCT/EP03/13965) covering its core founding drug discovery technology process entitled "Method For Providing Natural Therapeutic Agents With High Therapeutic Index" for applications to all therapeutic cytokine families.
The company pioneered the vision that natural evolution has created in the general population superior genetic variants of key human protein therapeutic drugs as compared to the first wave of reference protein therapeutic variants isolated and developed during the first biotech boom in the 80s, which currently constitute standard of care.
"We have always believed that our technology has wide potential in the industry for discovery of second generation products. Our IFN and EPO products have been granted IP in all major countries in which we filed a product patent application, including the EU and the USA. Our IP portfolio now extends to 53 patents and patent applications in more than 19 countries. Importantly, the European patent office has now granted our technology broad product protection rights across all cytokine families. The granting of such broad IP product rights is relatively unusual and has been achieved in this case because GenOdyssee successfully demonstrated successful application of its technology across multiple products in various cytokine families," said Dr. David Brown, senior executive advisor for science & bus dev to GenOdyssee.
|SOURCE GenOdyssee SA|
Copyright©2008 PR Newswire.
All rights reserved